December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.470 -0.090 (-1.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
From Candel Therapeutics
Via GlobeNewswire
How Is The Market Feeling About Candel Therapeutics?
 
Via Benzinga
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments. 
Via Stocktwits
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Major Indexes Falter; Dow Drops Over 550 Points
The Dow Jones Industrial Average is down 556 points midday, heading for its worst daily percentage loss since mid January, while the S&P 500 Index and Nasdaq Composite sit firmly in the red as well. 
Via Talk Markets
Topics Stocks Stocks / Equities
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice
CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 
Via Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call
The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments. 
Via Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
From Candel Therapeutics
Via GlobeNewswire
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
From Candel Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
What's Going On With Candel Therapeutics Shares Friday?
Candel shares are moving lower on Friday after the company priced its $80 million underwritten public offering of shares and pre-funded warrants. 
Via Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Candel Therapeutics Announces Pricing of Public Offering
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces $80 Million Proposed Public Offering
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Shares Are Up Today: What's Going On?
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are trading higher Thursday potentially driven by continued momentum following the company's announcement of positive phase 3 trial results for its... 
Via Benzinga
Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The stock market experienced a wave of optimism on Wednesday, driven by the latest inflation report. The Nasdaq 100 surged 1.7%, achieving a new record high. 
Via Benzinga
Topics Economy
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
 
Via Benzinga
Topics Economy
Candel Therapeutics Stock Surges Over 100% - Here's Why
Candel Therapeutics reports phase 3 trial success for CAN-2409 in prostate cancer, showing improved disease-free survival and safety consistency. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.